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Background: Lapatinib is a dual tyrosine kinase inhibitor which
interrupts the HER2/neu and epidermal growth factor receptor
(EGFR) family pathways in solid tumors. It is used for the treatment
of patients with advanced or metastatic breast cancer whose tumors
- ii -
overexpress HER2. Majority of patients who initially respond to the
treatment will eventually progress due to acquired resistance. The
defect in cell cycle regulation via increased levels of cyclin
D-CDK4/6 complexes is a well-known mechanism of the acquired
resistance to lapatinib. Thus, CDK4/6 inhibition can be considered as
an attractive strategy to overcome lapatinib resistance. In this study,
antitumor effect of palbociclib, a CDK4/6 inhibitor was investigated
whether it can be used as a new strategy to treat lapatinib resistant
cells by modulating cell cycle regulation.
Methods: Acquired lapatinib resistant SK-BR-3 cells are established
by treating lapatinib consistently for 7 months. The characteristics of
lapatinib resistance (LR) cell lines were evaluated by MTT, FACS,
Western blotting, qPCR, methylation assay and transcriptome analysis.
The antitumor effects of palbociclib in SK-BR-3 LR cell lines were
evaluated through changes in proliferative ability using MTT and
colony forming assay. Mechanism of action was analyzed by BrdU
assay, β-galactosidase assay, Western blotting assay for signal
- iii -
transduction molecules and IFA.
Results: In SK-BR-3 LR cells, the change of the molecules that
were related to the G1/S transition of cell cycle was prominent. It
was confirmed that cell cycle progression and proliferation were
significantly faster in SK-BR-3 LR cells compared to parental cells.
Overexpression of cyclin D1 and CDK6 was shown in SK-BR-3 LR
cells but cyclin-dependent kinase inhibitor, p16 and p14 were
suppressed. Cyclin D1 and CDK6 were upregulated at the
transcription level, and the epigenetic suppression of CDKN2A was
observed. Palbociclib inhibited the cell cycle progression and reduced
the cell viability significantly in SK-BR-3 LR cells by cell cycle
arrest via blocking hyper-phosphorylation of Rb. Palbociclib also
induced autophagic cell death in SK-BR-3 LR cells but not in
SK-BR-3 parental cells. Furthermore, palbociclib showed antitumor
activity against HER2 targeted therapy resistant patient derived
xenograft (PDX) with CDKN2A defect and cyclin D1 upregulation.
- iv -
Conclusion: The changes of cell cycle molecules that were related to
G1/S transition was observed in SK-BR-3 LR cells. Deficiency in
CDKN2A and upregulation of cyclin D1 led to the increased cell
cycle progression and proliferation in SK-BR-3 LR cells. CDK4/6
inhibitor palbociclib showed antitumor effect in SK-BR-3 LR cells
through modulating cell cycle in vitro and in HER2-directed therapy
resistant PDX model. These results suggest that inhibition of cyclin
D1 by palbociclib could be an effective strategy for treating lapatinib
resistance.
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HER2 positive breast cancer subtype accounts for 20-25% of breast
cancer, and it is highly proliferative by HER2 dependent signal
cascade activation. In this signaling cascade, pathways related to
proliferation, survival, and invasion such as PI3K/AKT and ERK are
present, resulting in tumorigenesis, cellular proliferation, survival,
invasion, and metastasis of cancer cells [1, 2]. HER2 directed therapy
including trastzumab, pertuzumab, lapatinib and TDM-1 are currently
using in the clinic and showed survival benefit for HER2 positive
breast cancer [3, 4].
Lapatinib is a dual tyrosine kinase inhibitor which interrupts the
HER2/neu and epidermal growth factor receptor (EGFR) pathways in
solid tumors. It is used for the treatment of patients with advanced
or metastatic breast cancer whose tumors overexpress HER2.
Majority of patients who initially respond to the treatment will
eventually progress due to acquired resistance. Therefore, it is
- 2 -
necessary to study resistance mechanism and explore strategies to
overcome acquired resistance [5-7].
One of the well-known mechanism of lapatinib resistance is cell
cycle deregulation. Activation of cyclin D-CDK4/6 complex is one of
the mechanisms of lapatinib resistance [8, 9]. During the transition
from G1 to S phase Rb played a role as a tumor suppressor at this
checkpoint. Rb binds to the transcription factor E2F to inhibit its
function. If cyclin D1 forms a complex with CDK4/6, this complex
induced inhibitory phosphorylation of Rb. Eventually, it results in
E2F-mediated activation, resulting in G1/S transition and promoting
cell proliferation [10]. The G1/S cell cycle is destroyed in many
cancers, and its dysregulation is known to be a major resistance
mechanism [11, 12]. Therefore, CDK4/6 inhibitor that suppresses this
pathway is considered to be a novel treatment [9, 13]. Palbociclib has
been proposed as a drug targeting G1/S cell cycle progression and is
actively used in hormone-receptor positive breast cancer [14, 15].
However, limited information is available for HER2 targeted therapy
- 3 -
resistance HER2 positive breast cancer.
In this study, I investigated that the epigenetic modulation of
cyclin-dependent kinase inhibitor (CKI) and the upregulation of cyclin
D1 have altered characteristics of SK-BR-3 LR cells and have been
shown to be overcome by CDK4/6 inhibitor. And I suggest that
CDK4/6 inhibitor, palbociclib can be used as a therapeutic strategy to
lapatinib resistant HER2 positive breast cancer.
- 4 -
MATERIALS AND METHODS
1. Reagents and antibodies
Lapatinib and palbociclib were kindly provided by GSK (London, UK)
and Pfizer (NY, USA), respectively and they dissolved in dimethyl
sulfoxide (DMSO) and stored at -80 ℃. Antibodies against
Caspase-3, Cyclin D1, LC3B, pRb, p21 (S780) were purchased from
Cell signaling Technology (MA, USA) Antibodies against CDK4,
CDK6, E2F-1, p14, Rb, SMP30, Lamin B1 were purchased from Santa
Cruz (CA, USA). Antibodies against p16, PARP were purchased from
BD Biosciences (CA, USA). Antibodies against thymidylate synthase
(TS) were purchased from Abcam (Cambridge, UK). Antibodies
against Actin were purchased from Sigma Aldrich (MO, USA).
2. Cell lines and cell cultures
Human HER2 amplified breast cancer cell line (SK-BR-3) was
- 5 -
purchased from the American Culture Collection (Cell Bank; Seoul,
South Korea). This cell line was cultured in RPMI 1640 (Thermo
Fisher Scientific Inc., MA, USA) supplemented with 10 % fetal
bovine serum (Welgene; Gyeongsan-si, South Korea) and 10 μg/mL
gentamicin (Cellgro; VA, USA) at 37 ℃ in a 5 % CO/95 % air
humidified atmosphere.
3. Generations of lapatinib resistant SK-BR-3 cells
SK-BR-3 Lapatinib resistance cell lines were generated by treating
lapatinib consistently. Starting from 30 nmol/L and gradually
increasing to 10 μmol/L over 7 months. Cell viability assay was
conducted to confirm resistance. A clonal selection was conducted and
two lapatinib resistant SK-BR-3 clones (LR#2, LR#5) that have
similar characteristics with pools of lapatinib resistant were selected.
Cells were continuously treated 3 μmol/L of lapatinib in RPMI 1640
medium containing 10 % fetal bovine serum and 10 μg/mL
- 6 -
gentamicin.
4. Cell viability assay
Cells were seeded at a density of 0.2-3 x  in 100 ㎕/well in 96-
well plates and incubated at 37 ℃ in 5 % CO/95 % air humidified
atmosphere for overnight. Lapatinib and palbociclib treated with
gradually increasing concentrations (dose ranges are 0-10 μmol/L and
0-5 μmol/L, respectively). Lapatinib treated for 3 days and palbociclib
treated for 5 days and then 50 ㎕ of 3-(4,5-dimethylthiazol
-2-yl)-2,5-diphenyltetrazolium bromide solution (Sigma Aldrich) was
added and the plates were incubated at 37 ℃ for 4 hours. After
removed the media, formazan crystals were dissolved with 150 ㎕ of
DMSO. By VersaMax microplate reader (Molecular Devices; CA,
USA), the absorbance was measured at 540 nm. The absorbance and
IC50 of lapatinib were analyzed with Sigma Plot software (Statistical
Package for the Social Sciences, Inc. (SPSs); IL, USA). There were 6
- 7 -
replicates were included in each analysis and independent experiment
was repeated at least 3 times.
5. Cell proliferation assay
Cells (1 x ) were seeded in 6-well plates and incubated overnight
at 37 ℃ in 5 % CO. The number of cells was counted every 24
hours or 48 hours. The growth rates of each day were normalized
with the value of the first day.
6. Cell cycle analysis
Cells were harvested, fixed in 70% ethanol, and then stored at –20
℃ at least 48 hours. After fixation, they were treated with RNase A
(Sigma Aldrich) at 37 ℃ for 1 hour. The cells were stained with 20
μg/mL propidium iodide (Sigma Aldrich) and the contents of DNA
were measured by Fluorescence-activated Cell Sorting (FACS)
- 8 -
Calibur flow cytometer (BD Biosciences). 10,000 cells were analyzed
in each experimental group.
7. Transcriptome analysis
Total RNA was isolated from sample using Trizol reagent (Molecular
research center, Inc., OH, USA) according to the manufacturer's
guidelines. Randomly fragmented the purified RNA for sequencing
with a short read and reverse-transcribed the cleaved RNA fragment
into cDNA. Attached different adapters to both ends of the prepared
cDNA fragment and ligated them. cDNA fragments were amplified
with PCR. Sequencing service was provided by Macrogen Inc. (Seoul,
South Korea). Proceeded with quality control analysis of raw reads
obtained through sequencing. Mapped the readers to the reference
genome using the HISAT2 (v2.0.5) program considering the splice,
and then create the aligned reads, Proceeded with transcript assembly
through StringTIe (v1.3.3b) program using information of reference
- 9 -
based on aligned reads. Calculate the amount of expression obtained
by transcript quantification of each samples as a normalization value
considering transcript length and depth of coverage. Expression profile
was extracted by performing within normalization with Fragments
Per Kilobase of transcript per Million mapped reads (FPKM) or Read
Per Kilobase of Transcript per Million mapped reads (RPKM).
8. Genomic DNA and mRNA extraction, RT-PCR and
relative quantitative PCR
Genomic DNA was extracted using the DNeasy purification kit
(Qiagen; Hilden, Germany) according to the manufacturer's
instructions. RNA was extracted using Trizol reagent (Molecular
research center) according to the manufacturer’s protocol. 6 μg of
total RNA was used for cDNA synthesis with random hexamers.
RNA expression level were analyzed by IQTM5 Optical Module
(BIO-RAD, CA, USA). Relative qPCR was done with a denaturation
- 10 -
step at 95 ℃ for 10 minutes, followed by 30 cycles of denaturation at
95 ℃ for 1 minute, primer annealing at 60 ℃ for 30 seconds, and
primer extension at 72 ℃ for 45 seconds. And a final extension at 72
℃ for 5 minutes was done and then stored at 4 ℃. The DNA copy
number and RNA expression value was normalized with that of
Actin. The primer sequence are provided below.
9. Western blot analysis
Cells were collected and added extraction buffer (50 mmol/L Tris-Cl
(pH 7.4), 150 mmol/L NaCl, 1 % NP40, 0.1 % sodium deoxycholate,
0.1 % sodium dodecyl sulfate (SDS), 50 mmol/L sodium fluoride, 1
- 11 -
mmol/L sodium pyrophosphate, 2 mmol/L phenylmethylsulfonyl
fluoride, 1 mg/mL pepstatin A, 0.2 mM leupeptin, 10 μg/mL aprotinin,
1 mmol/L sodium vanadate, 1 mmol/L nitrophenylphosphate, and 5
mmol/L benzamidine) on ice for 30 minutes. Equal amounts of
proteins were separated on an 8-15 % SDS-polyacrylamide gel. After
the resolved proteins were transferred onto nitrocellulose membranes
the blots were probed with primary antibodies at 4 ℃ for overnight.
Using enhanced chemiluminescence system according to the
manufacturer’s protocols (Amersham Biosciences; NJ, USA),
antibodies were detected.
10. Methylation sequencing
Genomic DNA was extracted using DNeasy purification kit (Qiagen).
DNA fragments were prepared using SureSelect Methyl-Seq Library
Prep Kit (Agilent; CA, USA) according to preparation guide.
Hybridized genomic DNA using SureSelect Methyl-Seq Kit reagents
- 12 -
(Agilent) and protocol. Hybrids were captured on Dynabeads MyOne
streptavidin beads (Thermo Fisher Scientific Inc.; MA, USA), and
then eluted. By bisulfate conversion, modified unmethylated C
residues and the di-tagged DNA was enriched in PCR, resulting in
double-stranded DNA (dsDNA) with the Illumina sequences for use
on the HiSeq platform. The sequencing was done by Macrogen Inc.
The raw sequence reads are filtered based on quality. The only
uniquely mapped reads are selected to sort, index and PCR duplicates
are removed with SAMBAMBA (v0.5.9). The methylation ratio of
every single cytosine location within on-target region is extracted
from the mapping results using ‘methylratio.py’ script in BSMAP.
The results of the coverage profiles were calculated as a number of
C / effective CT counts for each cytosine in CpG, CHH and CHG.




Cells were lysis with pH 7.5 RIPA buffer and pre-clearing with bead.
Antibody incubation for overnight at 4 ℃. Adding 50 ㎕ of bead and
incubate for 4 hours at 4 ℃. Centrifuge at 2000 rpm and discard the
supernatant and washing with 700 ㎕. Repeat washing step 3 times
with RIPA buffer and 2 times with DPBS. Add 50 ㎕ of 2X sample
buffer and boiling at 100 ℃. Loading samples on gel.
12. Fraction
Resuspend cells with ice-cold lysis buffer with low NaCl
concentration. Incubate for 5-10 minutes on ice. Centrifuge at 3000
rpm for 5min and move the supernatant which is cytoplasmic
contents to new E-tube. Wash the pellet 3 times with low NaCl
buffer and resuspend the pellet with lysis buffer containing high NaCl
concentration. Incubate for 30 minutes on ice and centrifuge 13,000
- 14 -
rpm for 10 minutes to obtain supernatant which is nuclear contents.
13. BrdU assay
Cells were treated with 10-20 μmol/L BrdU for 60-90 minutes. Cells
were fixed in 70 % ethanol and stored at –20 ℃. After cells were
resuspended with phosphate/citric acid buffer, the DNA denaturation
was conducted by 4 mol/L HCl for 20 minutes at room temperature.
FITC-conjugated anti-BrdU (BD Biosciences) used to investigate the
rates of BrdU incorporation. Cells were treated with 7-AAD (BD
Biosciences) and fluorescence were analyzed by
Fluorescence-activated Cell Sorting (FACS) Calibur flow cytometer
(BD Biosciences).
14. siRNA transfection
The siRNA for CCND1, CDK4, CDK6 was purchased from
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Genolution (Seoul, South Korea). p21 siRNA was purchased from
Santa Cruz. SK-BR-3 LR cells were transfected with each siRNA at
a concentration of 100 or 200 nmol/L using G-fectin (Genolution)
according to the manufacturer’s instructions. After 24 hours of
incubation, cells were re-transfected with siRNA at the same
concentration. Cells were harvested after doubling time of SK-BR-3
LR cells. The sequence of CCND1, CDK4, CDK6 siRNA were
5'-CCACAGAUGUGAAGUUCAUUUCCAAUU-3', 5'-AAGUAAUCUC
UGUAGAAAGAUGGAGGA-3’, 5'-UUCUACGAAACAUUUCUGCAA-
3’. The sequence of the control siRNA was 5’-AAUUCUCCGAACG
UGUCACGUUU-3’.
15. Colony formation assay
Cells were plated at a density of 0.3-3 x  in 60 mm dishes and
incubated at 37 ℃ for overnight. SK-BR-3 parental and LR cells
were treated palbociclib every 3 days for 4 weeks or 2 weeks,
- 16 -
respectively. Colonies were fixed with 50 % methanol (Merck;
Darmstadt, Germany) and 0.1 % coomassie brilliant blue R-250
solution (Sigma Aldrich) for 2 hours. And the numbers are
normalized with the value of control does.
16. β-galactosidase assay
SK-BR-3 Parental and LR cells were treated palbociclib 3 times for
120 hours. Cells were fixed with 1X fixation solution and incubated in
β-galactosidase staining solution at 37 ℃ overnight. Procedures were
conducted according to the manufacturer’s guidelines of β
-galactosidase staining kit (Cell signaling Technology). Numbers of
senescent cells were counted.
17. Immunofluorescence assay
Cells were seeded on coverslips coated with poly-L-lysine. After 24
- 17 -
hours, cells were treated with palbociclib 3 times for 120 hours. Cells
were fixed and permeabilized with 100% methanol for 15 minutes
(Merck). Antibody against LC3B (Cell signaling Technology) was
added and incubated for overnight. 300 nmol/L of DAPI was stained.
Coverslips were mounted onto slides using Faramount aqueous
mouting medium (Dako, Glostrup, Denmark) and immunofluorescence
was visualized by Zeiss LSM 510 laser scanning microscope.
18. PDX study
PDX experiments were approved from the Institutional Animal Care
and Use Committee (IACUC) and conducted in the animal facility of
Seoul National University (Seoul, South Korea). Ten NOD scid
gamma (NSG) mice were purchased from Central Lab Animal Inc.
(Seoul, South Korea) to confirm that palbociclib works effectively to
HER2 targeted therapy resistant breast cancer that have high cyclin
D1 and low CDKN2A in the PDX model. Patient tissues were
- 18 -
transplanted subcutaneously into each mouse. When the tumor volume
reached 150 , the mice were divided into 2 groups randomly. One
group received vehicle (pH 4.0 sodium acetate 50 mmol/L) and the
other group were treated palbociclib (150 mg/kg) via oral gavage
once daily for 28 consecutive days. Tumor volume was calculated
using the formula : (wide x height)/2. After 28 days, the mice were
sacrificed with CO and the tumor tissues were excised for further
analysis.
19. Statistical analysis
Data were analyzed using SigmaPlot version 10.0 (SPSs). Results
were expressed as the mean ± standard deviation (S.D.) or standard
error (S.E.). A two side Student’s t-test was used when appropriate.
p-values less than 0.05 were considered statistically significant and
those less than 0.1 were considered meaningful. All experiments were
conducted in duplicate or triplicated and repeated at least twice.
- 19 -
Results
1. The accelerated cell proliferation and cell cycle
progression were exhibited in lapatinib resistance cells
Lapatinib resistant cell line was established from human HER2
amplified SK-BR-3 breast cancer cell line. Although SK-BR-3 cell
line was originally highly sensitive to lapatinib, by consistently
treating lapatinib, SK-BR-3 lapatinib resistance (LR) cell line
acquired resistance to lapatinib. Two lapatinib resistant clones (LR
clone #2, #5) were selected by clonal selection (Fig. 1) and confirmed
that their characteristics were similar to their pool. Resistance to
lapatinib of SK-BR-3 LR cells was confirmed by growth inhibitory
assay (Fig. 2). SK-BR-3 LR cells and its clones had different
characteristics compared to SK-BR-3 parental cells, especially in
terms of proliferation rates and cell cycle progression (Fig. 3, 4).
They showed that accelerated proliferation and cell cycle progression.
These results indicate that SK-BR-3 LR cells are resistant to
- 20 -
lapatinib and had a new trait in comparison with the SK-BR-3
parental cell line. And also, I anticipated that I could find a
mechanism to overcome the lapatinib resistance by analyzing these
changed properties in SK-BR-3 LR cells.
- 21 -
Fig 1. SK-BR-3 Lapatinib resistance cells were generated by
treating lapatinib consistently.
Lapatinib resistance cells were established by treating lapatinib for 7
months. Parental cells were generated by DMSO treatment for the
same period. A clonal selection was conducted.
- 22 -
Figure 2. Cell viability after lapatinib treatment in lapatinib
resistant SK-BR-3 LR cells.
Growth inhibition was analyzed by the MTT assay. Lapatinib was
treated for 72 hours as indicated lapatinib concentrations.
- 23 -
Figure 3. Proliferation rates of SK-BR-3 parental and LR cells
were analyzed.
Proliferation rates were measured every 24 hours for 5 days. Cell
number was normalized with that of 24 hours. (** p<0.05).
- 24 -
Figure 4. Cell cycle progression was investigated by FACS.
Cells were harvested after cell cycle arrest for 6 hours and released
for additional 24 hours. Identified changes in cell cycle progression
during the same time period.
- 25 -
2. Expression of cell cycle-related molecules altered in
SK-BR-3 LR cells.
Since cell cycle progression and cell proliferation rates were increased
in SK-BR-3 LR cells compared to parental cells, it was expected that
there would be changes related to the cell cycle. Transcriptome data
showed that the altered expression of the molecules related to the
G1/S transition was observed (Fig. 5, Table 1). CCND1 and CDK6
mRNA levels were upregulated not only in SK-BR-3 LR cells but
also in LR clones by qPCR (Fig. 6). Protein expression was observed
to follow mRNA expression pattern (Fig. 7).
To determine which molecules among cyclin D1, CDK4, and CDK6
had the greatest effect on the altered characteristics of SK-BR-3 LR
cells. To confirm this, siRNA transfection was used to observe
whether changes in proliferation rate or cell cycle progression induced
when each molecule was knocked down.
As a result, pRb and E2F-1 protein expression were decreased by
- 26 -
knockdown of CCND1, CDK4, and CDK6 (Fig. 8). However, the
proliferation rate and cell cycle progression were reduced only when
CCND1 was suppressed (Fig. 9, 10). These data suggest that cyclin
D1 is a factor that causes changes in the characteristics of SK-BR-3
LR cells.
- 27 -
Figure 5. Alteration of transcriptome expression was observed
in SK-BR-3 LR cells.
The difference between SK-BR-3 parental and LR cells were
analyzed by RNA sequencing. Among the three cell lines (SK-BR-3,
SK-BR-3 Parental, SK-BR-3 LR), it was confirmed that remarkable
changes induced in SK-BR-3 LR cells.
- 28 -
Table 1. mRNA level of SK-BR-3 LR cells versus SK-BR-3
parental cells.
The molecules related to G1/S transition were changed.
- 29 -
Figure 6. qPCR data of molecules related in G1/S transition.
CCND1 and CDK6 were upregulated in SK-BR-3 LR cells. mRNA
expression was renormalized by the value of SK-BR-3 parental cells.
(**p<0.05).
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Figure 7. Basal expression levels of protein were confirmed by
Western blot.
In SK-BR-3 LR cells, protein level of cyclin D1, CDK6 were
increased and p14, p16 levels were suppressed as seen at the mRNA
level. Actin was used as loading control.
- 31 -
Figure 8. Changes in protein expression after gene knockdown
using siRNA.
Cyclin D1, CDK4, CDK6 knockdown induced downregulation of pRb
and E2F-1. pRb downregulation was most prominent after cyclin D1
knockdown using siCCND1 transfection.
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Figure 9. Proliferation rate was analyzed after siRNA
transfection.
Proliferation rate was reduced only after siCCND1 transfection in
SK-BR-3 LR cells. The number of cells was counted once every two
days and renormalized with the number of 24 hours. The cells were
harvested at 120 hours timepoint of proliferation assay to confirm
knockdown.
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Figure 10. FACS was conducted to observe alteration of cell
cycle progression after siRNA transfection.
After siCCND1 transfection, fraction of cells in G1 phase was
increased whereas fraction of S and G2/M phase was decreased.
- 34 -
3. Upregulation of cyclin D1 induced due to defect of
CDKN2A
I tried to identify the cause of cyclin D1 upregulation. First, I
checked the copy number of genomic DNA and confirmed that there
was no evidence of genomic DNA amplification (Fig 11).
Interestingly, CDKN2A, inhibitor of cyclin D-CDK4/6 complexes, was
defected at the mRNA level (Fig 12). CDKN2A suppression was also
observed at the protein level (Fig 7). These changes were also not
associated with the genomic DNA copy number (Fig 11) and
methylation sequencing revealed that histone methylation increased at
SK-BR-3 LR cells compared to the parental cells (Table 2). These
were confirmed by 5-aza treatment, methyltransferase inhibitor. 5-aza
treatment resulted in an increase of CDKN2A mRNA levels in
SK-BR-3 LR cells (Fig 13).
Through these data, I could confirm that changes in G1/S cell
cycle molecules, such as CCND1 upregulation and epigenetic
- 35 -
suppression of CDKN2A are the mechanisms of accelerated
proliferation and cell cycle progression in SK-BR-3 LR cells.
- 36 -
Figure 11. Genomic DNA copy number was observed by qPCR.
CCND1, CDKN2A copy number alteration were not observed in
SK-BR-3 LR cells compared to parental cells.
- 37 -
Figure 12. CDKN2A mRNA level was analyzed by qPCR.
CDKN2A was defected in SK-BR-3 LR cells. mRNA expression was
renormalized by the value of SK-BR-3 parental cells. (**p<0.05).
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Table 2. Comparison of the degree of methylation in SK-BR-3
parental and LR cells.
CDKN2A was fully methylated in SK-BR-3 LR cells. A value of 1
means fully methylated in CpG sites of overall gene. The closer the
value is to 1, the more methylation occurs.
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Figure 13. mRNA level was analyzed after 5-aza treatment.
After 5-aza treatment, the mRNA level of CDKN2A genes were
increased in SK-BR-3 LR cells. Expression of mRNA level after 5
μmol/L of 5-aza treatment was normalized with control (0 μmol/L) by
fold change. (**p<0.05, *p<0.1).
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4. Palbociclib induced G1 cell cycle arrest in SK-BR-3
LR cells.
I hypothyzed that CDK4/6 inhibitor which inhibits cyclin D activity
might be effective in suppressing the growth of SK-BR-3 LR cells.
Palbociclib, a CDK4/6 inhibitor, was observed to be more effective in
SK-BR-3 LR cells than SK-BR-3 parental cells (Fig. 14).
Next, I investigated the mechanisms of palbociclib effects.
Considering that the effect of palbociclib decreases as the cell
doubling time passes, I treated palbociclib during each cell’s doubling
time. As a result, it was confirmed that G1 arrest was induced by
palbociclib through decrease of pRb and E2F-1. I observed that the
degree of DNA synthesis was reduced, and it was confirmed by the
reduction of thymidylate synthase (TS) expression (Fig. 15). When I
observed the degree of S phase incorporation by BrdU assay under
the same conditions, I found that cell cycle progression was
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significantly reduced by palbociclib in SK-BR-3 LR cells (Fig 16).
In addition, I investigated the cause of the cyclin D1 upregulation
despite of palbociclib treatment. Previous studies have shown that
p21, a CDK inhibitor, may induce accumulation of cyclin D1 [16-18].
GSK3β induces nuclear export of cyclin D1 which is phosphorylated
at the threonine 286 site. However, when p21 binds to cyclin D1, it
overrides this site and stabilizes the cyclin D1-CDK4/6 complex in
the nucleus [19-21]. p21 was increased after palbociclib treatment in
SK-BR-3 LR cells (Fig 15). When p21 was knocked down, cyclin D1
and CDK4 expression were decreased. Conversely, when p21
upregulated by palbociclib treatment, cyclin D1 and CDK4 expression
were also induced (Fig 17). The interaction between cyclin D1 and
p21 was increased in SK-BR-3 LR cells compared with parental cells,
and the interactions between cyclin D1 and CDK4, CDK6 were also
increased. However, p21 suppression in SK-BR-3 LR cells reduced
the interaction of cyclin D1-CDK6 complexes, indicating that cyclin
D1 upregulation induced by palbociclib was due to p21 (Fig 18).
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Knockdown of p21 also resulted in a decrease of cyclin D1, CDK4,
CDK6 in the nucleus (Fig 19).
These findings indicate that palbociclib inhibited cellular
proliferation by inducing G1 cell cycle arrest.
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Figure 14. Cell viability with palbociclib was analyzed by MTT
for 120 hours.
After 120 hours treatment of palbociclib, cell viability of SK-BR-3 LR
cells were remarkably decreased compared to SK-BR-3 parental cells.
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Figure 15. Protein expressions of molecules related in G1/S
transition were inhibited by palbociclib treatment.
pRb and E2F-1 protein expression were downregulated after
palbociclib treatment. Thymidylate synthase expression was also
decreased by palbociclib treatment. Duration of palbociclib treatment
was matched with doubling time of each cell’s (Parental : 51 hours,
LR : 14 hours).
- 45 -
Figure 16. Palbociclib inhibited G1/S transition in SK-BR-3 LR
cells.
In SK-BR-3 LR cells, palbociclib induced G1 arrest and reduced S
phase incorporation. Palbociclib treated for each cell’s doubling time.
(**p<0.05, *p<0.1)
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Figure 17. Knockdown of p21 induced cyclin D1 and CDK4
downregulation.
When p21 was downregulated by siRNA, cyclin D1 and CDK4 also
suppressed. When palbociclib was treated, p21 was slightly increased,
and cyclin D1 and CDK4 followed the tendency.
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Figure 18. Comparison interaction of cyclin D1 and CDK4/6
between SK-BR-3 parental and LR cells.
In SK-BR-3 LR cells, the interaction between cyclin D1-CDK6 or
p21 was increased compared to parental cells. Cyclin D1-CDK6
interaction decreased after p21 suppression by siRNA.
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Figure 19. Knockdown of p21 altered the level of cyclin D1
complex in the nucleus.
Knockdown of p21 by siRNA induced downregulation of CDK4,
CDK6, and cyclin D1 in the nucleus.
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5. Autophagy was induced by palbociclib in SK-BR-3
LR cells.
The colony formation assay was performed to determine whether
palbociclib showed anti-proliferative effect in long-term culture
system. As a result, I observed that the colony formation was
significantly reduced by palbociclib treatment in the SK-BR-3 LR
cells, and thus palbociclib was confirmed to be effective also in the
long-term (Fig. 20).
I assumed the antitumor effect of palbociclib observed in SK-BR-3
LR cells is mediated by apoptotic cell death [22, 23]. However, despite
the cell death was induced by palbociclib in SK-BR-3 LR cells,
neither the sub-G1 population nor the cleaved forms of PARP and
caspase-3 were observed (Fig 21, 22).
Palbociclib has been known to exert its effects through senescence
through several previous studies [24-26]. I investigated whether
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palbociclib causes senescence in SK-BR-3 LR cells. I could not
observe any increase in SMP30 (Fig. 21) [27], a senescence marker,
and confirmed that no stained cells were observed even though β
-galactosidase assay (Fig. 23), another senescence confirmation
method, was performed. These data provide evidence that the effect
of palbociclib does not occur through senescence and apoptosis in
SK-BR-3 LR cells.
To determine which of cell death mechanisms the effect of
palbociclib is occupied by, I tested whether autophagy can be induced
by palbociclib in SK-BR-3 LR cells [23, 25]. Treatment of palbociclib
in SK-BR-3 LR cells showed an increase in autophagy marker,
LC3-II (Fig. 21) and LC3 puncta formation (Fig. 24).
Taken together, I conclude that palbociclib exerts its effects
through autophagy in SK-BR-3 LR cells.
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Figure 20. Colony forming assay was conducted to confirm
long-term growth inhibition effect of palbociclib.
SK-BR-3 parental and LR cells were subjected to colony formation
assay with three times of palbociclib treatment considering each cell’s
doubling time. In SK-BR-3 LR cells, colony formation rates were
remarkably reduced by palbociclib.
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Figure 21. Modulation of apoptosis, autophagy, senescence
signaling.
There was no increase in cleaved PARP, cleaved caspase-3 and
SMP30 by palbociclib. LC3-II expression was induced by palbociclib
in dose-dependent manner. Palbociclib was treated 3 times for 120
hours.
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Figure 22. Sub-G1 population.
Palbociclib was added for every 48 hours for 120 hours. Sub-G1
population was not statistically significantly increased in SK-BR-3
LR cells by palbociclib treatment compared to parental cells. (*ns : no
statistical significance)
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Figure 23. Senescence induction was analyzed by
β-galactosidase assay.
Palbociclib was treated 3 times for 120 hours. There was no
β-galactosidase staining in SK-BR-3 LR cells.
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Figure 24. IFA was conducted to determine whether autophagy
was induced by palbociclib.
LC3B puncta were detected after palbociclib treatment for 120 hours.
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6. Palbociclib was effective in patient-derived
xenograft model.
IMX57 PDX model was established from hormone receptor positive
and HER2 amplified breast cancer patients who failed many prior
lines of HER2 targeted therapies including trastuzumab and lapatinib
and endocrine therapy. In this tumor model, the copy number gain of
the CCND1 gene was detected (Fig 25). with upregulation of cyclin
D1 protein expression and loss of p14, p16 which were coded by
CDKN2A (Fig 26). This model is expected to be effective for
palbociclib because of the increased G1/S transition due to
overactivation of cyclin D1 and CDKN2A loss as in SK-BR-3 LR
cells. We transplanted PDX sample in mouse at 8 weeks and treated
palbociclib (150 mg/kg) daily for 4 weeks. As a result, significant
tumor growth was delayed in the palbociclib-treated group (Fig 27).
Reduced cell proliferation was observed by decrease of Ki-67 and TS
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expression (Fig 28). These results suggest that palbociclib may be an
effective treatment strategy for patients with breast cancer who were
hyperactivated by cyclin D1 due to loss of CDKN2A as they
acquired resistance to HER2 targeted therapy.
- 58 -
Figure 25. CCND1 amplification in IMX57 PDX model.
CCND1 and ERBB2 genes are amplified in IMX57.
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Figure 26. IMX57 have similar characteristics with SK-BR-3
LR cells.
In SK-BR-3 LR cells and IMX57, cyclin D1 was upregulated and
CDKN2A was downregulated compared to SK-BR-3 parental cells.
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Figure 27. Palbociclib treatment was effective in PDX
established from HER2 amplified breast cancer patient failed to
lapatinib.
In the vehicle treated group, tumor size was continuously increased,
but tumor growth was delayed in palbociclib treated group.
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Figure 28. IHC staining of PDX tumor.
Pathological examination was performed using tumor tissue of PDX
model after the drug treatment ended. Hematoxylin and eosin (H&E)
staining were used and the scale bars represent 5 mm (x10). In the
palbociclib treated group, the reduction in TS and Ki-67 expression
showed decrease in proliferation.
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Discussion
Lapatinib is a HER2 targeted small molecular tyrosine kinase inhibitor
that has been effective in HER2 positive breast cancer and gastric
cancer [3, 4]. However, due to acquired resistance, there was
limitation to use lapatinib for long term treatment [5-7]. Although the
mechanism causing this resistance has been actively researched and
various drugs have been developed, the overcoming mechanism has
not been studied much yet.
In this study, I tried to find a way to overcome the lapatinib
resistance and identify its mechanism. For this, lapatinib resistance
SK-BR-3 cells were established and their characteritics were
analyzed. SK-BR-3 LR cells showed remarkably faster cell
proliferation than SK-BR-3 parental cells. But HER2 signaling
pathway, which causes proliferation in HER2 positive cells was
downregulated [1]. HER2 downstream molecules were first observed
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because the altered SK-BR-3 LR cells traits may have been caused
by an abnormal increase in proliferation signaling [7, 28-30].
However, the activity of PI3K and MAPK, which are typical HER2
downstream pathways, was decreased. In addition, activity of STAT3,
which is another proliferation signal, was increased but it did not
affect the viability of SK-BR-3 LR cells. Taken together, these
indicate that there might be other mechanism involved in the rapid
proliferation of SK-BR-3 LR cells.
By transcriptome data and methylation analysis, it has been found
that unlike the SK-BR-3 parental cells, cell cycle-related molecules,
especially genes inducing G1/S transition, are upregulated and
inhibitors suppressing them are epigenetically inhibited. Previous
studies have shown that cell cycle deregulation is one of the
mechanisms of lapatinib resistance [8, 9]. The cyclin D-CDK4/6
pathway plays an important role in the transition from G1 to S phase
during the cell cycle and is tightly regulated through checkpoint.
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However, excessive activation of these pathways is known to induced
tumorigenesis [11, 12] and drug resistance. In this regard, the cell
cycle progression was also abnormally increased in the SK-BR-3 LR
cells, so it could be assumed that inhibition of this pathway would
overcome this resistance. Like hypothesis, treatment with palbociclib,
which inhibits the cyclin D-CDK4/6 pathway, proved to be more
effective in SK-BR-3 LR cells than SK-BR-3 parental cells.
I examined the mechanism of palbociclib in SK-BR-3 LR cells. In
short term effect, S phase incorporation was significantly reduced by
palbociclib in SK-BR-3 LR cells compared to SK-BR-3 parental cells.
Palbociclib was also very effective in the long term culture system,
confirmed by CFA. Several previous studies have reported that the
effect of palbociclib induced via senescence. Recently, however,
palbociclib has been reported to cause autophagy. Palbociclib have
shown to induce autophagy and apoptosis in hepatocellular carcinoma
(HCC) through the activation of 5’-AMP-activated protein kinase
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(AMPK) and the inhibition of protein phosphatase 5 (PP5) [23]. In
SK-BR-3 LR cells, it was confirmed that palbociclib induces
autophagy. In addition, I confirmed that the antitumor effect of
palbociclib was also applied in vivo using PDX model established
from breast cancer patient with resistance to HER2 targeted therapy
that have characteristics of high level of cyclin D1 with CDKN2A
loss similar to SK-BR-3 LR cells.
In conclusion, palbociclib does not overcome the resistance of
lapatinib, but treatment alone is effective enough in SK-BR-3 LR
cells. In addition, these results showed that palbociclib can be applied
not only to hormone receptor positive breast cancer but also to other
subtypes. It was also expected that it would be possible to perform
clinical application of palbociclib to HER2 targeted therapy resistant
breast cancer by verifying the effect in PDX model.
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국문 초록
Lapatinib은 HER2와 epidermal growth factor receptor (EGFR)을 차단
하는 이중 tyrosine kinase 억제제로써 HER2 양성 전이성 유방암에서
효과적으로 작용하나 치료 중 내성이 나타난다. Cyclin D-CDK4/6 복합
체의 과도한 활성으로 인한 무분별한 세포주기 활성은 lapatinib에 대한
획득 내성 기전으로 알려져 있다. 따라서 lapatinib 내성을 극복하기 위
한 전략으로 cyclin D-CDK4/6 경로를 활용할 수 있을 것으로 판단하였
다. 본 연구에서는 CDK4/6 억제제인 palbociclib이 세포주기를 조절하여
lapatinib 내성 세포에서 항종양효과를 나타내는지 확인하고, 그 기전을
연구하여 lapatinib 내성 HER2 양성 유방암의 새로운 치료 전략으로 사
용될 수 있는지 연구하였다.
HER2 양성 유방암 세포주 SK-BR-3에 lapatinib의 농도를 증가시키면서
장기간 처리하여 내성이 생긴 세포주를 수립하고 transcriptome data,
FACS, Western blotting, qPCR, methylation assay 등을 통해 lapatinib
내성 세포주의 특성을 확인하였다. MTT, BrdU assay와 콜로니 형성 분
석의 변화를 통해 palbociclib의 세포 증식억제 효과를 관찰하였고, 세포
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주기에 관여하는 분자와 신호 전달경로에 관여하는 분자들의 발현 변화
및 β-galactosidase assay와 IFA를 통해 기전을 연구하였다.
Lapatinib 내성 세포에서는 세포주기의 G1/S 이행과 관련된 분자들의 변
화가 두드러지게 나타났으며 SK-BR-3 부모 세포와 비교하여 세포주기
의 진행과 증식 속도가 증가되어 있었다. 이와 관련하여 lapatinib에 대
한 내성 기전 중 하나인 cyclin D-CDK4/6 복합체의 활성이 증가하고
이들을 억제하는 CKI인 CDKN2A가 메틸화로 인해 억제되어 있었다.
Cyclin D1과 CDK6 발현은 전사수준에서 증가 되었고 CDKN2A는 후성
유전 억제나 이 결과를 통해 CDKN2A의 억제로 인해 cyclin D1의 활성
화가 유발되었다고 판단하였다. Palbociclib은 Rb의 인산화를 억제하여
lapatinib 내성 HER2 양성 유방암 세포주에서 세포주기 진행을 억제하고
세포 생존 능력을 현저하게 감소시킨다는 것을 확인하였으며 palbociclib
이 lapatinib 내성 세포에서 자가소화작용을 유발하여 세포성장 억제 효
과를 나타낸다는 것을 확인하였다. HER2 표적 치료제에 내성이 생겨
CDKN2A의 억제와 cyclin D1의 증가가 일어난 HER2 양성 유방암 환
자로부터 얻은 환자유래 종양 동물 모델에서도 palbociclib이 효과적으로
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종양의 성장을 억제함을 확인하였다.
따라서 palbociclib에 의한 세포 주기 경로의 억제는 lapatinib 내성
HER2 양성 유방암 치료에 효과적인 전략이 될 수 있으며 본 연구 결과
를 통해 palbociclib이 호르몬 수용체 양성 유방암뿐만 아니라 다른 아형
에서도 적용이 가능하다는 것을 보여주었고 환자유래 종양 동물 모델에
서 검증하여 빠른 임상 적용을 할 수 있을 것이라 기대할 수 있다.
주요어 : HER2, lapatinib, 내성, 세포주기, CDK4/6 억제
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